Figures & data
Figure 1. IL-33 delays ovarian cancer tumor progression.
![Figure 1. IL-33 delays ovarian cancer tumor progression.](/cms/asset/3e0e7461-5a6c-4284-a9c4-73e556c60586/koni_a_1515058_f0001_oc.jpg)
Figure 2. IL-33 promotes an allergic like infiltration of the peritoneal cavity.
![Figure 2. IL-33 promotes an allergic like infiltration of the peritoneal cavity.](/cms/asset/987af640-80d1-4922-9f60-f3d586c04e76/koni_a_1515058_f0002_b.gif)
Figure 3. IL-33 promotes recruitment and activation of peritoneal CD4 T cells.
![Figure 3. IL-33 promotes recruitment and activation of peritoneal CD4 T cells.](/cms/asset/9d9ec808-36bf-414d-b646-527dfe7eaddc/koni_a_1515058_f0003_oc.jpg)
Figure 4. IL-33 promotes peritoneal CD4 T-cell and B cell activation and eosinophil recruitment.
![Figure 4. IL-33 promotes peritoneal CD4 T-cell and B cell activation and eosinophil recruitment.](/cms/asset/69f97e52-1283-4c21-9f80-09a5b8f56126/koni_a_1515058_f0004_oc.jpg)
Figure 5. IL-33 promotes activation of peritoneal macrophages.
![Figure 5. IL-33 promotes activation of peritoneal macrophages.](/cms/asset/f30f8c24-8441-4939-8b9d-e053ac2404df/koni_a_1515058_f0005_b.gif)
Figure 6. Maintenance of the Th2 response is necessary for the IL-33 mediated delay tumor progression in ovarian cancer.
![Figure 6. Maintenance of the Th2 response is necessary for the IL-33 mediated delay tumor progression in ovarian cancer.](/cms/asset/749deb01-6a96-48ab-abea-e1afddc45c33/koni_a_1515058_f0006_oc.jpg)